Although the majority of patients with acute myeloid leukemia (AML) treated with intensive
chemotherapy achieve a complete remission (CR), many are destined to relapse if treated …

Haematopoietic stem cell transplantation (HSCT) is central to the management of many
haematological disorders. A frequent complication of HSCT is acute graft-versus-host …

Mesenchymal stem cells (MSCs) are of particular interest for the treatment of immune-
related diseases owing to their immunosuppressive properties. In this study, we aimed to …

Graft-versus-host disease (GVHD) is the most important complication of allogeneic
hematopoietic stem cell transplantation (alloHSCT). We performed a prospective …

This collaborative initiative aimed to provide recommendations on the use of polyclonal
antithymocyte globulin (ATG) or anti-T lymphocyte globulin (ATLG) for the prevention of graft …

Acute graft versus host disease (aGVHD) remains the second leading cause of death
following allogeneic hematopoietic stem cell transplant (AHSCT). Over the last five years …

Cyclosporin-A has been known and used for a long time, since its “fast track” approval in the
early 80's. This molecule has rapidly demonstrated unexpected immunosuppressive …

Antithymocyte globulin (ATG) is used as prophylaxis against graft-versus-host disease
(GVHD). Current dosing regimens for ATG are empiric and weight-based, and do not …

Cyclosporine-A (CsA) is used to prevent acute graft-versus-host disease (aGvHD).
European Society for Blood and Marrow transplantation (EBMT) recommends a CsA target …

Hematopoietic stem cell transplantation activity in Europe : Current Opinion in Hematology
Hematopoietic stem cell transplantation activity in Europe : Current Opinion in Hematology Log …